CMC(603122)2024-03-22 16:00Financial Performance - Revenue for the reporting period was RMB 1,092.60 million, a decrease of 14.62% year-on-year[8] - Net profit attributable to shareholders of the listed company was RMB 47.19 million, a decrease of 42.96% year-on-year[8] - Revenue for the third quarter was RMB 267.93 million, with a net profit attributable to shareholders of RMB 13.15 million[6] - Total assets decreased by 6.26% to 1,461,406,215.62 in 2023 compared to 1,559,065,109.86 in 2022[22] - Revenue declined by 14.62% to 1,092,602,026.63 in 2023 from 1,279,666,218.81 in 2022[22] - Net profit attributable to shareholders dropped by 42.96% to 47,186,921.09 in 2023 from 82,719,667.82 in 2022[22] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 38.18% to 46,919,175.91 in 2023 from 75,895,588.47 in 2022[22] - Weighted average return on equity decreased by 3.50 percentage points to 4.06% in 2023 from 7.56% in 2022[22] - Basic earnings per share fell by 45.45% to 0.12 in 2023 from 0.22 in 2022[22] - Diluted earnings per share also decreased by 45.45% to 0.12 in 2023 from 0.22 in 2022[22] Cash Flow and Shareholder Information - Operating cash flow for the reporting period was RMB 11.28 million, an increase of RMB 41.65 million compared to the same period last year[8] - The company's operating cash flow turned positive in the second quarter and continued to be positive in the third quarter[1] - The number of ordinary shareholders at the end of the reporting period was 35,311, a decrease from 36,341 at the end of the previous month[3] - The largest shareholder, Hefu (Hong Kong) Holdings Limited, holds 55.00% of the company's shares[3] - Operating cash flow turned positive to 11,281,136.90 in 2023 from -30,366,164.41 in 2022[22] Strategic Adjustments and Business Focus - The company has reduced non-terminal medical product distribution business to focus on strategic adjustments and risk control[1] - The company has established a talent team to promote empowerment projects and increase customer stickiness[1] - The company is focusing on technological innovation and service capabilities to meet the increasing demands of the market[12][13] - The company signed medium and long-term contracts with medical institutions, covering 4 new provinces and adding over 20 new terminal customers[14] - The company's medical product distribution business focuses on sales and maintenance of radiotherapy equipment, as well as sales of immunodiagnostic and biochemical diagnostic equipment[14] - The company's hospital empowerment platform includes services such as key specialty co-construction, group hospital strategic planning, and clinical innovation research collaboration[21] - The company's integrated business platform provides value-added services to medical institutions, including unified procurement, distribution, and inventory management of reagents and consumables[14] Market and Industry Trends - The domestic in vitro diagnostics market has exceeded RMB 100 billion and is expected to continue growing due to increased health awareness and aging population[18] Technological Innovation and Product Development - The company launched a decision analysis integrated platform, with over 10 medical institutions deciding to adopt it by year-end[21] - The company's subsidiary, Heyi Information, will localize production of the surgical audio-visual imaging chain integration platform "Metaway" in mainland China[21] - The company collaborated with Zhejiang University's Computer Innovation Technology Institute to develop a clinical diagnostic assistance system using AI and big data analysis[21] Cross-Strait Collaboration and Resource Sharing - The company facilitated cross-strait medical resource sharing, assisting mainland medical institutions in training in Taiwan and introducing Taiwanese experts to mainland hospitals[14] Dividend Proposal - The company proposed a cash dividend of RMB 0.60 per 10 shares, totaling RMB 23,883,157.98 (tax included), pending shareholder approval[16]